[1] Riazi K,Azhari H,Charette JH,et al.The prevalence and incidence of NAFLD worldwide:A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2022,7(9):851-861. [2] Teng ML,Ng CH,Huang DQ,et al.Global incidence and prevalence of nonalcoholic fatty liver disease[J]. Clin Mol Hepatol,2023,29(Suppl):S32-S42. [3] Tincopa MA,Loomba R.Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Lancet Gastroenterol Hepatol,2023,8(7):660-670. [4] Lu R,Liu Y,Hong T.Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China:A narrative review[J]. Diabetes Obes Metab,2023,25(Suppl 1):13-26. [5] 廖佳倩,王国蓉,杨婧,等. 中国成人非酒精性脂肪性肝病患病率的meta分析[J]. 职业与健康,2023,39(16):2276-2281. [6] Le MH,Le DM,Baez TC,et al.Global incidence of non-alcoholic fatty liver disease:A systematic review and meta-analysis of 63 studies and 1 201 807 persons[J]. J Hepatol,2023,79(2):287-295. [7] 中国营养学会肥胖防控分会,中国营养学会临床营养分会,中华预防医学会行为健康分会,等. 中国居民肥胖防治专家共识[J]. 中华流行病学杂志,2022,43(5):18. [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会,范建高,等. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 实用肝脏病杂志,2018,21(2):30-39. [9] 刘嘉慧,刘靖. 2023年欧洲高血压学会新版高血压管理指南简评[J]. 中华高血压杂志,2023,31(10):908-910. [10] 郝雅娟,吴文强. WS/T 404《临床常用生化检验项目参考区间》的验证和评估[J]. 实用医技杂志,2016,23(1):73-75. [11] Devarbhavi H,Asrani SK,Arab JP,et al.Global burden of liver disease:2023 update[J]. J Hepatol,2023,79(2):516-537. [12] Xue R,Yang RX,Fan JG.Epidemiological trends and clinical characteristic of NAFLD/MAFLD in Asia[J]. J Dig Dis,2022,23(7):354-357. [13] Younossi ZM,Golabi P,Paik JM,et al.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH):A systematic review[J]. Hepatology,2023,77(4):1335-1347. [14] 曾子露,关琳,田昊宇,等. 沈阳地区青壮年非酒精性脂肪性肝病的流行趋势及危险因素分析[J]. 中国医科大学学报,2021,50(9):774-778. [15] 阮建文,高丽娟,梁雄飞,等. 海口地区体检人群非酒精性脂肪性肝病患病率调查分析[J]. 临床肝胆病杂志,2018,34(9):1925-1928. [16] 刘玲娇,余湘尤,虢小丽. 西安市职业人群非酒精性脂肪性肝病患病率及其危险因素调查研究[J]. 陕西医学杂志,2021,50(1):107-110. [17] 陈蒙,杨雪,朱守林. 连云港市社区居民非酒精性脂肪性肝病流行现状及影响因素[J]. 华南预防医学,2021,47(7):913-916. [18] Weng C,Shao Z,Xiao M,et al.Association of sex hormones with non-alcoholic fatty liver disease:An observational and Mendelian randomization study[J]. Liver Int,2024,44(5):1154-1166. [19] Lee C,Kim J,Jung Y.Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Cells,2019,8(10):1259. [20] Simon TG,Roelstraete B,Alkhouri N,et al.Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease[J]. Gut,2023,72(3):573-580. [21] De A,Bhagat N,Mehta M,et al.Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD[J]. J Hepatol,2024,80(2):e61-e62. [22] Kong L,Yang Y,Li H,et al.Prevalence of nonalcoholic fatty liver disease and the related risk factors among healthy adults:A cross-sectional study in Chongqing,China[J]. Front Public Health,2023,11:1127489. |